Beyond these, diverse genetic alterations involving RTKs, RAS, RAF kinases and pathway regulators lead to the aberrant activation of the MAPK pathway and highlight its central role in the pathogenesis of CNS tumors [8,25]. This evidence concerns the gene RAF1 and central nervous system neoplasm.